Cancer is the leading cause of death worldwide and this trajectory is predicted to continue for the next two decades. New therapeutic targets are providing cancer patients with improved outcomes and better quality of life. Boehringer Ingelheim is committed to developing targeted therapies for solid tumours and haematological malignancies and our oncology researchers are focused on the core pillars of Lung cancer and Haematology. Our robust early and late stage pipeline is geared to provide treatment solutions now and in the future.

We have a specialised cancer research centre in Vienna and have established close partnerships with important research organisations, and academic institutions. We work with many of the leading experts and forward-looking scientists from around the world and are always seeking new alliances with people and institutes that share our vision and commitment.
 
Boehringer Ingelheim is proud to have brought medicines to the Indian market which contribute towards improving and extending the lives of people with advanced lung cancer. We are committed to improving the lives of people with cancer through innovation and tailored treatment options.

 

References:

  1. Ferlay J shin HR, Bray F, Forman D. Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Intl J Cancer 2010; 127:2893-917.
  2. American Cancer society, cancer facts 7 figures 2012, Atlanta, GA: American Cancer society; 2012.